Media headlines about Biostar Pharmaceuticals (NASDAQ:BSPM) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Biostar Pharmaceuticals earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.0061083082168 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Biostar Pharmaceuticals (NASDAQ BSPM) opened at $1.75 on Wednesday. Biostar Pharmaceuticals has a fifty-two week low of $1.18 and a fifty-two week high of $4.30.
COPYRIGHT VIOLATION NOTICE: This story was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/11/15/biostar-pharmaceuticals-bspm-receiving-somewhat-favorable-news-coverage-accern-reports.html.
Biostar Pharmaceuticals, Inc (Biostar) is a holding company. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co, Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, manufactures and markets pharmaceutical products for various diseases and conditions in the People’s Republic of China (PRC or China).
Receive News & Ratings for Biostar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.